A.T. RAIMOVA¹, R.R. NABIEVA¹, E.I. MOROZOVA¹, A.A. KAMALOVA^1, 2

¹Kazan State Medical University, Kazan

²Children’s Republican Clinical Hospital, Kazan

Contact details:

Raimova A.T. — resident doctor of the Department of Hospital Pediatrics

Address: 49 Butlerov Str., 420012 Kazan, tel.: +7-960-053-22-22, e-mail: Adelina.raimova@yandex.ru

The review provides up-to-date information on the features of the hemostasis system, risk groups for thrombosis, and current recommendations for thromboprophylaxis in inflammatory bowel diseases (IBD) in children. The risk of thrombosis in IBD in children has been actively discussed in recent years due to a significant increase in the incidence of thrombosis in children with IBD compared to the population of healthy children. Thromboprophylaxis has long been an established practice in hospitalized adult patients with IBD, but recommendations for similar treatment in children have been limited so far. The COVID-19 pandemic has adjusted the existing recommendations for thromboprophylaxis in children. According to the latest publications, thromboprophylaxis should be considered in three groups of hospitalized patients: 1. children with the onset of acute severe UC; 2. all children with UC in postpubertal age and children in prepuberty with 1 or more risk factors, 3. children with CD, regardless of age, with 1 or more risk factors. It is important to increase awareness among specialists in the issues of identifying risk groups for thrombosis and its prevention among children with active IBD, especially those undergoing inpatient treatment.

Key words: inflammatory bowel disease, children, thromboprophylaxis, thrombosis, thromboembolic complications.

REFERENCES

1. Kuenzig M.E., Bitton A., Carroll M.W. et al. Inflammatory bowel disease increases the risk of venous thromboembolism in children: a population-based matched cohort study. J. Crohns Colitis, 2021, vol. 15, pp. 2031–2040.
2. Martine A. Aardoom, Renz C.W. Klomberg, Polychronis Kemos et al. The incidence and characteristics of venous thromboembolisms in paediatric-onset inflammatory bowel disease: a prospective international cohort study based on the PIBD-SET quality safety registry. J. Crohns Colitis, 2022, vol. 16, pp. 695–707.
3. Turner D., Ruemmele F.M., Orlanski-Meyer E. et al. Management of paediatric ulcerative colitis, part 2: acute severe colitis-an evidence-based consensus guideline from the European Crohn’s and Colitis Organization and the European Society of paediatric gastroenterology, hepatology and nutrition. J. Pediatr. Gastroenterol. Nutr, 2018, vol. 67 (2), rr. 292–310.
4. Torrente F., Meade S., Benchimol E.I. et al. Thromboprophylaxis use in paediatric inflammatory bowel disease: an international RAND appropriateness panel. J. Crohns Colitis, 2022, vol. 16 (10), pp. 1609–1616.
5. Giannotta M., Tapete G., Emmi G. et al. Thrombosis in inflammatory bowel diseases: what’s the link? Thrombosis J, 2015, vol. 13, p. 14. DOI: 10.1186/s12959-015-0044-2
6. Borota A.V., Borota A.A., Onishchenko E.V. Thrombotic complications in inflammatory bowel diseases. Rossiyskiy zhurnal gastroenterologii, gepatologii, koloproktologii, 2019, no. 29 (2), pp. 23–26 (in Russ.).
7. Harvey P.R., McNulty D., Coupland B. et al. The risk of venous thromboembolism in children with inflammatory bowel disease. Inflamm. Bowel Dis, 2024, izae249. DOI: 10.1093/ibd/izae249
8. Sabapathy C.A., Djouonang T.N., Kahn S.R. et al. Incidence trends and mortality from childhood venous thromboembolism: a population-based cohort study. J. Pediatr, 2016, vol. 172, rr. 175–180.
9. Park E.S., Choi H.S., Lee K.S. et al. Venous thromboembolism in children and young adults in Korea: analysis of the Korean health insurance review and assessment service database. J. Korean Med. Sci, 2019, vol. 34 (49), r. 316.
10. Kappelman M.D., Horvath-Puho E., Sandler R.S. et al. Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study. Gut, 2011, vol. 60 (7), rr. 937–943.
11. Branchford B.R., Carpenter S.L. The Role of inflammation in venous thromboembolism. Front. Pediatrics, 2018, vol. 6, r. 142.
12. Vazquez-Garza E., Jerjes-Sanchez C., Navarrete A. et al. Venous thromboembolism: thrombosis, inflammation, and immunothrombosis for clinicians. J. Thromb. Thrombolysis, 2017, vol. 44, rr. 377–385.
13. Coremans L., Strubbe B., Peeters H. Venous thromboembolism in patients with inflammatory bowel disease: review of literature and practical algorithms. Acta Gastroenterol. Belg, 2021, vol. 84, rr. 79–85.
14. Tsiolakidou G., Koutroubakis I.E. Thrombosis and inflammatory bowel disease-the role of genetic risk factors. World J. Gastroenterol, 2008, vol. 14, rr. 4440–4444.
15. Owczarek D., Cibor D., Głowacki M.K. et al. In f lammatory bowel disease: epidemiology, pathology and risk factors for hypercoagulability. World J. Gastroenterol, 2014, vol. 20, rr. 53–63.
16. Zhang X.Y., Dong H.C., Wang W.F. et al. Risk of venous thromboembolism in children and adolescents with inflammatory bowel disease: A systematic review and meta-analysis. World J Gastroenterol, 2022, vol. 28 (16), rr. 1705–1717.
17. Gala D., Newsome T., Roberson N. et al. Thromboembolic events in patients with inflammatory bowel disease: a comprehensive overview. Diseases, 2022, vol. 10 (4), r. 73.
18. Al Nabhani Z.; Dietrich G.; Hugot J.P. et al. Nod2: The intestinal gate keeper. PLoS Pathog, 2017, vol. 13.
19. Kronman M.P., Zaoutis T.E., Haynes K. et al. Antibiotic exposure and IBD development among children: A population-based cohort study. Pediatrics, 2012, vol. 130, rr. 794–803.
20. Alkim H., Koksal A.R., Boga S. et al. Etiopathogenesis, prevention, and treatment of thromboembolism in inflammatory bowel disease. Clin. Appl. Thromb. Hemost, 2017, vol. 23 (6), rr. 501–510.
21. Jaffray J., Mahajerin A., Young G. et al. A multi-institutional registry of pediatric hospital-acquired thrombosis cases: the Children’s Hospital-Acquired Thrombosis (CHAT) project. Thromb. Res, 2018, vol. 161, rr. 67–72.
22. Mahajerin A., Branchford B.R., Amankwah E.K. et al. Hospital associated venous thromboembolism in pediatrics: a systematic review and meta-analysis of risk factors and risk-assessment models. Haematologica, 2015, vol. 100, rr. 1045–1050.
23. Bhandari S., Mohammed Abdul M.K., Dhakal B. et al. Increased rate of venous thromboembolism in hospitalized inflammatory bowel disease patients with Clostridium difficile infection. Inflamm. Bowel Dis, 2017, vol. 23, rr. 1847–1852.
24. Weng M.T., Park S.H., Matsuoka K. et al. Incidence and risk factor analysis of thromboembolic events in East Asian Patients with inflammatory bowel disease, a multinational collaborative study. Inflamm. Bowel Dis, 2018, vol. 24, rr. 1791–1800.
25. Olivera P.A., Zuily S., Kotze P.G. et al. International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease. Nat. Rev. Gastroenterol. Hepatol, 2021, vol. 18, pp. 857–873. DOI: 10.1038/s41575-021-00492-8
26. Bhatia P., Singh N. Homocysteine excess: Delineating the possible mechanism of neurotoxicity and depression. Fundam. Clin. Pharmacol, 2015, vol. 29, pp. 522–528.
27. Senchenkova E., Seifert H., Granger D.N. et al. Hypercoagulability and platelet abnormalities in inflammatory bowel disease. Semin Thromb Hemost, 2015, vol. 41, rr. 582–589.
28. Soendergaard C., Kvist P.H., Seidelin J.B. et al. Tissue-regenerating functions of coagulation factor XIII. J. Thromb. Haemost, 2013, vol. 11, rr. 806–816.
29. De Laffolie J., Ballauff A., Wirth S. et al. Occurrence of thromboembolism in paediatric patients with inflammatory bowel disease: data from the CEDATA-GPGE registry. Front. Pediatr, 2022, vol. 10.
30. Richard N., Leroyer A., Ley D. et al. Incidence and risk factors for thromboembolic events in pediatric-onset inflammatory bowel disease: A French population-based study. Digestive and liver disease: official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2025, vol. 57 (2), rr. 584–594.
31. Sharma N., Tewatia P., Harvey P.R. et al. Controversies in venous thromboembolism risk assessment in inflammatory bowel disease: a narrative review. Diagnostics, 2024, vol. 14, r. 2112.
32. Majoor C.J., Sneeboer M.M., de Kievit A. et al. The Influence of corticosteroids on hemostasis in healthy subjects. J. Thromb. Haemost, 2016, vol. 14, rr. 716–723.
33. Sarlos P., Szemes K., Hegyi P. et al. Steroid but not biological therapy elevates the risk of venous thromboembolic events in inflammatory bowel disease: a meta-analysis. J. Crohn’s Colitis, 2018, vol. 12, rr. 489–498.
34. Federal’nye klinicheskie rekomendatsii “Bolezn’ Krona”, 2024 [Federal clinical guidelines «Crohn’s disease», 2024], available at: https://cr.minzdrav.gov.ru/preview-cr/682_2
35. Federal’nye klinicheskie rekomendatsii “Yazvennyy kolit u detey”, 2024 [Federal clinical guidelines «Ulcerative colitis in children», 2024], available at: https://cr.minzdrav.gov.ru/preview-cr/391_3.